Press Release
<< Back
“Our financial results reported today reflect the successes and challenges of 2019. While we achieved record revenue for Feraheme and gained our third FDA approval in two years, we faced some challenges, namely the readout of the PROLONG study and the
FINANCIAL RESULTS FOR THE PERIODS ENDED
Fourth Quarter Financial Results
($M) | Three Months Ended |
||||||
2019 | 2018 | ||||||
Revenues | $ | 89.7 | $ | 88.1 | |||
Feraheme | 41.7 | 35.2 | |||||
Makena | 25.6 | 46.9 | |||||
Intrarosa | 6.5 | 5.9 | |||||
Other product revenue | (0.4 | ) | 0.1 | ||||
Collaboration revenue | 16.3 | — | |||||
Costs and expenses | $ | 283.6 | $ | 106.9 | |||
Cost of product sales | 43.3 | 28.7 | |||||
Research and development | 16.5 | 12.2 | |||||
Selling, general and administrative expenses | 68.8 | 66.0 | |||||
Impairment of assets | 155.0 | — | |||||
Operating loss | $ | (193.9 | ) | $ | (18.8 | ) | |
Adjusted EBITDA1 | $ | (5.8 | ) | $ | 1.5 |
____________________________
1 See summaries of GAAP to non-GAAP adjustments at conclusion of this press release.
Revenues
During the fourth quarter ended
- In the fourth quarter of 2019 sales of Feraheme totaled
$41.7 million , compared with$35.2 million in the same period in 2018, sales of Makena totaled$25.6 million , compared with$46.9 million in the same period in 2018, and sales of Intrarosa totaled$6.5 million , compared with$5.9 million in the same period in 2018. - Included in revenue for the fourth quarter of 2019 was $16.3 million of collaboration revenue recognized in connection with a termination and settlement agreement entered into with
Daiichi Sankyo, Inc. (DSI) related to a clinical trial collaboration agreement that AMAG acquired as part of the Perosphere acquisition. Under the terms of the settlement agreement with DSI, AMAG received$10.0 million in cash and recognized an additional $6.3 million of deferred revenue inDecember 2019 .
Costs and Expenses
Costs and expenses in the fourth quarter ended
- During the fourth quarter of 2019, the company identified indicators of impairment for the Makena subcutaneous auto-injector, Intrarosa and Vyleesi asset groups related to i) the unfavorable
FDA Advisory Committee recommendation for Makena onOctober 29, 2019 and ii) the completion of a strategic review, which resulted in the company's intention to divest Intrarosa and Vyleesi. Total impairment charges of$155.0 million were recorded in a separate operating expense line in the fourth quarter of 2019.
Operating Loss and Adjusted EBITDA
- The company reported an operating loss in the fourth quarter ended
December 31, 2019 of$193.9 million , which included the$155.0 million of impairment charges discussed above, compared to an operating loss of$18.8 million for the same period last year. - The company reported an adjusted EBITDA loss of
$5.8 million in the fourth quarter of 2019, compared with adjusted EBITDA of$1.5 million for the same period last year.1
Full Year Financial Results | |||||||
($M) | Twelve Months Ended |
||||||
2019 | 2018 | ||||||
Revenues | $ | 327.8 | $ | 474.0 | |||
Feraheme | 167.9 | 135.0 | |||||
Makena | 122.1 | 322.3 | |||||
Intrarosa | 21.4 | 16.2 | |||||
Other product revenue | (0.2 | ) | 0.4 | ||||
Collaboration and other revenue | 16.6 | 0.1 | |||||
Costs and expenses | $ | 773.3 | $ | 521.0 | |||
Cost of product sales | 107.2 | 215.9 | |||||
Research and development | 64.9 | 44.8 | |||||
Acquired in-process research and development | 74.9 | 32.5 | |||||
Selling, general and administrative expenses | 286.6 | 227.8 | |||||
Impairment of assets | 232.3 | — | |||||
Restructuring | 7.4 | — | |||||
Operating loss | $ | (445.5 | ) | $ | (47.0 | ) | |
Adjusted EBITDA1 | $ | (65.0 | ) | $ | 120.8 |
Revenues
Revenues totaled
- Feraheme achieved record revenue of
$167.9 million in 2019, an increase of 24% over 2018, and market share of 17.7%. The overall IV iron market grew 12.0% in 2019 from 2018. - Makena revenues totaled
$122.1 million in 2019, compared with$322.3 million in 2018. This decrease was primarily due to a decrease in sales of the Makena intramuscular (IM) product caused by IM supply disruptions and generic competition, which resulted in the company ultimately removing the IM product, including its authorized generic, from the market. Partially offsetting the decrease in Makena IM revenues was an increase in Makena subcutaneous auto-injector revenues. - Intrarosa revenues increased 32% to
$21.4 million in 2019, compared with$16.2 million in 2018.
Costs and Expenses
Costs and expenses in 2019 totaled
- Cost of product sales decreased $108.7 million year-over-year, primarily due to a decrease in amortization related to the Makena IM product that was fully impaired in the second quarter of 2019.
- SG&A expenses increased
$58.8 million to$286.6 million in 2019, compared with$227.8 million in 2018. SG&A expenses in 2018 included a reversal of$49.6 million related to a Makena sales milestone that the company determined was not likely to be paid. Excluding this expense reversal, SG&A increased by$9.2 million , which was primarily driven by the commercial launch of Vyleesi inSeptember 2019 . - Research and development expenses increased
$20.0 million to$64.9 million in 2019, primarily related to the development costs for the ciraparantag and AMAG-423 programs.
Operating Loss and Adjusted EBITDA
- The company reported an operating loss of
$445.5 million in 2019, compared with an operating loss of$47.0 million in 2018. - The company reported an adjusted EBITDA loss of
$65.0 million in 2019, compared with adjusted EBITDA of$120.8 million in 2018.1
Balance Sheet
- As of
December 31, 2019 , the company’s cash and investments totaled$171.8 million . - As of
December 31, 2019 long-term debt totaled$320.0 million (representing the principal amount outstanding of the 2022 convertible notes).
“Despite the challenges that the company faced throughout 2019, the growth in Feraheme revenues emerged as a bright spot for the year. Even with a soft fourth quarter for Makena, we managed our spend to achieve our adjusted EBITDA financial guidance for the year,” said
2020 FINANCIAL GUIDANCE2
The company reaffirms the following financial guidance for 2020.
($M) | 2020 Financial Guidance |
Total revenue | |
Operating income | |
Non-GAAP adjusted EBITDA |
2 See reconciliation of 2020 GAAP to non-GAAP financial guidance at conclusion of this press release.
2020 KEY PRIORITIES
- Complete successful CEO transition
- Divest Intrarosa and Vyleesi to align with the new strategic direction
- Drive continued Feraheme growth
- Work with the FDA to maintain patient access to Makena
- Advance ciraparantag and AMAG-423 development programs
- Pursue ex-
U.S. portfolio partnering opportunities - Meet or exceed financial guidance
CONFERENCE CALL AND WEBCAST ACCESS
DIAL-IN NUMBER
International Dial-in Number: (702) 495-1202
Conference ID: 5865557
Conference ID: 5865557
A telephone replay will be available from approximately
The webcast with slides will be accessible through the Investors section of AMAG’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
USE OF NON-GAAP FINANCIAL MEASURES
AMAG has presented certain non-GAAP financial measures, including non-GAAP adjusted EBITDA (earnings before income taxes, depreciation and amortization). These non-GAAP financial measures exclude certain amounts, expenses or income, from the corresponding financial measures determined in accordance with accounting principles generally accepted in the
ABOUT AMAG
AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging our development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas, including women’s health. For additional company information, please visit www.amagpharma.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking information about
Such risks and uncertainties include, among others, risks that the FDA will withdraw approval of Makena in line with the recommendation of the Advisory Committee; the FDA could take other adverse action related to Makena given the findings and recommendation of the Advisory Committee; AMAG may not be able to generate additional efficacy data that will be satisfactory to the FDA (if the FDA permits AMAG to submit additional data to support or as a condition to the continued commercialization of Makena); healthcare providers may be reluctant to continue to prescribe the Makena auto-injector or the FDA may require that the Makena label include information on the PROLONG study, restrictions to the current indication or the insertion of new warnings or precautions; AMAG is unable to generate sufficient cash to satisfy its debt obligations and could face challenges undertaking fundraising, restructuring or strategic transactions in order to meet these obligations, including under convertible notes due
AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. AMAG Pharmaceuticals®, the logo and designs, Feraheme® and Vyleesi ® are registered trademarks of
- Tables Follow -
Condensed Consolidated Statements of Operations
(unaudited, amounts in thousands, except for per share data)
Three Months Ended |
Year Ended |
||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
Revenues: | |||||||||||||||
Feraheme | $ | 41,653 | $ | 35,204 | $ | 167,947 | $ | 135,001 | |||||||
Makena | 25,601 | 46,888 | 122,064 | 322,265 | |||||||||||
Intrarosa | 6,520 | 5,888 | 21,417 | 16,218 | |||||||||||
Other | (395 | ) | 67 | (238 | ) | 368 | |||||||||
Total product sales, net | 73,379 | 88,047 | 311,190 | 473,852 | |||||||||||
Collaboration revenue | 16,299 | — | 16,400 | — | |||||||||||
Other revenue | 31 | 75 | 161 | 150 | |||||||||||
Total revenues | 89,709 | 88,122 | 327,751 | 474,002 | |||||||||||
Costs and expenses: | |||||||||||||||
Cost of product sales | 43,322 | 28,716 | 107,193 | 215,892 | |||||||||||
Research and development expenses | 16,476 | 12,211 | 64,853 | 44,846 | |||||||||||
Acquired in-process research and development | — | — | 74,856 | 32,500 | |||||||||||
Selling, general and administrative expenses | 68,873 | 66,030 | 286,600 | 227,810 | |||||||||||
Impairment of assets | 154,978 | — | 232,336 | — | |||||||||||
Restructuring expenses | — | — | 7,420 | — | |||||||||||
Total costs and expenses | 283,649 | 106,957 | 773,258 | 521,048 | |||||||||||
Operating loss | (193,940 | ) | (18,835 | ) | (445,507 | ) | (47,046 | ) | |||||||
Other income (expense): | |||||||||||||||
Interest expense | (6,510 | ) | (6,571 | ) | (25,709 | ) | (51,971 | ) | |||||||
Loss on debt extinguishment | — | — | — | (35,922 | ) | ||||||||||
Interest and dividend income | 636 | 2,120 | 4,285 | 5,328 | |||||||||||
Other (expense) income | (134 | ) | (10 | ) | 428 | (74 | ) | ||||||||
Total other expense, net | (6,008 | ) | (4,461 | ) | (20,996 | ) | (82,639 | ) | |||||||
Loss from continuing operations before income taxes | (199,948 | ) | (23,296 | ) | (466,503 | ) | (129,685 | ) | |||||||
Income tax (benefit) expense | (21 | ) | (2,550 | ) | (47 | ) | 39,654 | ||||||||
Net loss from continuing operations | (199,927 | ) | (20,746 | ) | (466,456 | ) | (169,339 | ) | |||||||
Discontinued operations: | |||||||||||||||
Income from discontinued operations | — | — | — | 18,873 | |||||||||||
Gain on sale of CBR business | — | (2,506 | ) | — | 87,076 | ||||||||||
Income tax expense | — | (975 | ) | — | 2,371 | ||||||||||
Net (loss) income from discontinued operations | — | (1,531 | ) | — | 103,578 | ||||||||||
Net loss | $ | (199,927 | ) | $ | (22,277 | ) | $ | (466,456 | ) | $ | (65,761 | ) | |||
Basic and diluted earnings per share: | |||||||||||||||
Loss from continuing operations | $ | (5.89 | ) | $ | (0.60 | ) | $ | (13.71 | ) | $ | (4.92 | ) | |||
Income from discontinued operations | — | (0.04 | ) | — | 3.01 | ||||||||||
Total | $ | (5.89 | ) | $ | (0.64 | ) | $ | (13.71 | ) | $ | (1.91 | ) | |||
Weighted average shares outstanding used to compute earnings per share (basic and diluted): | 33,945 | 34,560 | 34,030 | 34,394 | |||||||||||
Condensed Consolidated Balance Sheets
(unaudited, amounts in thousands)
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 113,009 | $ | 253,256 | |||
Marketable securities | 58,742 | 140,915 | |||||
Accounts receivable, net | 94,163 | 75,347 | |||||
Inventories | 31,553 | 26,691 | |||||
Prepaid and other current assets | 19,100 | 18,961 | |||||
Note receivable | — | 10,000 | |||||
Total current assets | 316,567 | 525,170 | |||||
Property and equipment, net | 4,116 | 7,521 | |||||
422,513 | 422,513 | ||||||
Intangible assets, net | 23,620 | 217,033 | |||||
Operating lease right-of-use asset | 23,286 | — | |||||
Deferred tax assets | 630 | 1,260 | |||||
Restricted cash | 495 | 495 | |||||
Other long-term assets | — | 1,467 | |||||
Total assets | $ | 791,227 | $ | 1,175,459 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 27,021 | $ | 14,487 | |||
Accrued expenses | 177,079 | 129,537 | |||||
Current portion of convertible notes, net | — | 21,276 | |||||
Current portion of operating lease liability | 4,077 | — | |||||
Current portion of acquisition-related contingent consideration | 17 | 144 | |||||
Total current liabilities | 208,194 | 165,444 | |||||
Long-term liabilities: | |||||||
Convertible notes, net | 277,034 | 261,933 | |||||
Long-term operating lease liability | 19,791 | — | |||||
Long-term acquisition-related contingent consideration | — | 215 | |||||
Other long-term liabilities | 89 | 1,212 | |||||
Total liabilities | 505,108 | 428,804 | |||||
Commitments and Contingencies (Note P) | |||||||
Stockholders’ equity: | |||||||
Preferred stock, par value |
— | — | |||||
Common stock, par value |
339 | 346 | |||||
Additional paid-in capital | 1,297,917 | 1,292,736 | |||||
Accumulated other comprehensive loss | (3,239 | ) | (3,985 | ) | |||
Accumulated deficit | (1,008,898 | ) | (542,442 | ) | |||
Total stockholders’ equity | 286,119 | 746,655 | |||||
Total liabilities and stockholders’ equity | $ | 791,227 | $ | 1,175,459 |
Condensed Consolidated Statements of Cash Flows
(unaudited, amounts in thousands, except for per share data)
Years Ended |
|||||||
2019 | 2018 | ||||||
Cash flows from operating activities: | |||||||
Net loss | $ | (466,456 | ) | $ | (65,761 | ) | |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |||||||
Depreciation and amortization | 27,324 | 172,223 | |||||
Impairment of long-lived assets | 232,336 | — | |||||
Provision for bad debt expense | — | 678 | |||||
Amortization of premium/discount on purchased securities | (95 | ) | 87 | ||||
Write-down of inventory | 19,767 | 5,176 | |||||
(Gain) loss on disposal of fixed assets | — | (99 | ) | ||||
Non-cash equity-based compensation expense | 19,198 | 19,916 | |||||
Non-cash IPR&D expense | 18,029 | — | |||||
Loss on debt extinguishment | — | 35,922 | |||||
Amortization of debt discount and debt issuance costs | 15,242 | 15,658 | |||||
(Gain) loss on sale of marketable securities, net | (265 | ) | (1 | ) | |||
Change in fair value of contingent consideration | (270 | ) | (49,607 | ) | |||
Deferred income taxes | 404 | 41,166 | |||||
Non-cash lease expense | 2,725 | — | |||||
Gain on sale of the CBR business | — | (87,076 | ) | ||||
Transaction costs | — | (14,111 | ) | ||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | (18,816 | ) | 16,995 | ||||
Inventories | (19,253 | ) | (454 | ) | |||
Prepaid and other current assets | (113 | ) | (6,097 | ) | |||
Accounts payable and accrued expenses | 52,747 | (32,568 | ) | ||||
Deferred revenues | (6,400 | ) | 8,658 | ||||
Other assets and liabilities | (1,800 | ) | 95 | ||||
Net cash (used in) provided by operating activities | (125,696 | ) | 60,800 | ||||
Cash flows from investing activities: | |||||||
Proceeds from sales or maturities of marketable securities | 98,321 | 85,342 | |||||
Purchases of marketable securities | (14,815 | ) | (89,956 | ) | |||
Milestone payment for Vyleesi developed technology | (60,000 | ) | — | ||||
Proceeds from the sale of the CBR business | — | 519,303 | |||||
Note receivable | — | (10,000 | ) | ||||
Capital expenditures | (2,544 | ) | (2,534 | ) | |||
Net cash provided by investing activities | 20,962 | 502,155 | |||||
Cash flows from financing activities: | |||||||
Long-term debt principal payments | — | (475,000 | ) | ||||
Payments to repurchase 2019 Convertible Notes | (21,417 | ) | — | ||||
Payment of premium on debt extinguishment | — | (28,054 | ) | ||||
Payment of contingent consideration | (72 | ) | (119 | ) | |||
Payments for repurchases of common stock | (13,730 | ) | — | ||||
Proceeds from the issuance of common stock under the ESPP | 1,506 | — | |||||
Proceeds from the exercise of common stock options | 30 | 3,881 | |||||
Payments of employee tax withholding related to equity-based compensation | (1,830 | ) | (2,682 | ) | |||
Net cash used in financing activities | (35,513 | ) | (501,974 | ) | |||
Net (decrease) increase in cash, cash equivalents and restricted cash | (140,247 | ) | 60,981 | ||||
Cash, cash equivalents and restricted cash at beginning of the year | 253,751 | 192,770 | |||||
Cash, cash equivalents and restricted cash at end of the year | $ | 113,504 | $ | 253,751 | |||
Supplemental data of cash flow information: | |||||||
Cash (refunded) paid for taxes | $ | (202 | ) | $ | 5,345 | ||
Cash paid for interest | $ | 10,667 | $ | 48,757 | |||
Non-cash investing and financing activities: | |||||||
Right-of-use assets obtained in exchange for lease obligations | $ | 18,455 | $ | — | |||
Settlement of note receivable in connection with |
$ | 10,000 | $ | — |
Reconciliation of Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations
Three Months Ended
(unaudited, amounts in thousands)
Revenue | Cost of product sales | Research & development | Selling, general & administrative | Asset impairment charges | Operating Loss / Adjusted EBITDA | ||||||||||||||||||
GAAP | $ | 89,709 | $ | 43,322 | $ | 16,476 | $ | 68,873 | $ | 154,978 | $ | (193,940 | ) | ||||||||||
Depreciation and intangible asset amortization | — | (12,666 | ) | (101 | ) | (684 | ) | — | |||||||||||||||
Stock-based compensation | — | (245 | ) | (793 | ) | (3,779 | ) | — | |||||||||||||||
Charges related to impairment | — | (14,893 | ) | — | — | (154,978 | ) | ||||||||||||||||
Non-GAAP Adjusted | $ | 89,709 | $ | 15,518 | $ | 15,582 | $ | 64,410 | $ | — | $ | (5,801 | ) |
Reconciliation of Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations
Three Months Ended
(unaudited, amounts in thousands)
Revenue | Cost of product sales | Research & development | Selling, general & administrative | Operating Loss / Adjusted EBITDA | |||||||||||||||
GAAP | $ | 88,122 | $ | 28,716 | $ | 12,211 | $ | 66,030 | $ | (18,835 | ) | ||||||||
Depreciation and intangible asset amortization | — | (13,714 | ) | (9 | ) | (372 | ) | ||||||||||||
Non-cash inventory step-up adjustments | — | (126 | ) | — | — | ||||||||||||||
Stock-based compensation | — | (215 | ) | (637 | ) | (4,465 | ) | ||||||||||||
Adjustments to contingent consideration | — | — | — | 432 | |||||||||||||||
Acquisition related costs | — | — | — | (1,257 | ) | ||||||||||||||
Non-GAAP Adjusted | $ | 88,122 | $ | 14,661 | $ | 11,565 | $ | 60,368 | $ | 1,528 |
Reconciliation of Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations
Twelve Months Ended
(unaudited, amounts in thousands)
Revenue | Cost of product sales | Research & development | Selling, general & administrative | Asset impairment charges | Acquired IPR&D | Restructuring | Operating Loss / Adjusted EBITDA | ||||||||||||||||||||||||
GAAP | $ | 327,751 | $ | 107,193 | $ | 64,853 | $ | 286,600 | $ | 232,336 | $ | 74,856 | $ | 7,420 | $ | (445,507 | ) | ||||||||||||||
Depreciation and intangible asset amortization | — | (24,764 | ) | (572 | ) | (1,988 | ) | — | — | — | |||||||||||||||||||||
Stock-based compensation | — | (871 | ) | (2,844 | ) | (14,818 | ) | — | — | — | |||||||||||||||||||||
Acquired IPR&D | — | — | — | — | — | (74,856 | ) | — | |||||||||||||||||||||||
Charges related to impairment | — | (19,729 | ) | — | — | (232,336 | ) | — | — | ||||||||||||||||||||||
Restructuring charges | — | — | — | — | — | — | (7,420 | ) | |||||||||||||||||||||||
Acquisition related costs | — | — | — | (270 | ) | — | — | — | |||||||||||||||||||||||
Non-GAAP Adjusted | $ | 327,751 | $ | 61,829 | $ | 61,437 | $ | 269,524 | $ | — | $ | — | $ | — | $ | (65,039 | ) |
Reconciliation of Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations
Twelve Months Ended
(unaudited, amounts in thousands)
Revenue | Cost of product sales | Research & development | Selling, general & administrative | Acquired IPR&D | Operating Loss / Adjusted EBITDA | ||||||||||||||||||
GAAP | $ | 474,002 | $ | 215,892 | $ | 44,846 | $ | 227,810 | $ | 32,500 | $ | (47,046 | ) | ||||||||||
Depreciation and intangible asset amortization | — | (158,446 | ) | (21 | ) | (1,592 | ) | — | |||||||||||||||
Non-cash inventory step-up adjustments | — | (3,728 | ) | — | — | — | |||||||||||||||||
Stock-based compensation | — | (802 | ) | (2,533 | ) | (16,614 | ) | — | |||||||||||||||
Adjustments to contingent consideration | — | — | — | 49,607 | — | ||||||||||||||||||
Acquired IPR&D | — | — | — | — | (32,500 | ) | |||||||||||||||||
Acquisition related costs | — | — | — | (1,257 | ) | — | |||||||||||||||||
Non-GAAP Adjusted | $ | 474,002 | $ | 52,916 | $ | 42,292 | $ | 257,954 | $ | — | $ | 120,840 |
Reconciliation of 2019 Financial Guidance of Non-GAAP Adjusted EBITDA
(Unaudited, amounts in millions)
Operating income | |
Depreciation | 2 |
Stock-based compensation | 16 |
Adjusted EBITDA |
Share Count Reconciliation
(unaudited, amounts in millions)
Three Months Ended |
Twelve Months Ended |
|||||||||||
2019 | 2018 | 2019 | 2018 | |||||||||
Weighted average basic shares outstanding | 33.9 | 34.6 | 34.0 | 34.4 | ||||||||
Employee equity incentive awards | — | 3 | — | 3 | — | 3 | — | 3 | ||||
GAAP diluted shares outstanding | 33.9 | 34.6 | 34.0 | 34.4 | ||||||||
Employee equity incentive awards | — | 4 | 0.3 | 4 | — | 4 | 0.3 | 4 | ||||
Non-GAAP diluted shares outstanding | 33.9 | 34.9 | 34.0 | 34.7 |
3 Employee equity incentive awards would be anti-dilutive in this period.
4 Reflects the non-GAAP dilutive impact of employee equity incentive awards.
CONTACTS:
Investors:
908-627-3424
Media:
781-296-0722
Source: AMAG Pharmaceuticals, Inc.